Insight Molecular Diagnostics Inc. Common Stock IMDX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$103K-5.1% | -$109K-29.8% | -$113K-68.7% | -$115K-130% | -$98K-75.0% | ||
| $1.95M-49.3% | $4.06M+116% | $4.4M+521% | $4.26M+316% | $3.84M+178% | ||
| $949K-46.0% | $1.75M+65.7% | $1.97M+232% | $1.89M+167% | $1.76M+108% | ||
| $1M-52.1% | $2.31M+179% | $2.43M— | $2.36M— | $2.09M— | ||
| 51.3%-3.0pp | 57%+12.9pp | 55.2%— | 55.5%— | 54.3%— | ||
| $17.94M+71.7% | $15.91M+61.7% | $12.34M+21.8% | $11.28M+18.8% | $10.45M+10.3% | ||
| $7.54M+75.2% | $6.34M+60.8% | $5.25M+58.1% | $4.91M+64.0% | $4.3M+46.1% | ||
| $10.51M-1.3% | $10.63M+4.2% | $10.87M+15.6% | $10.89M+16.8% | $10.65M+1.9% | ||
| $49.74M-17.9% | $53.43M-13.5% | $63.73M+46.1% | $66.1M+79.5% | $60.59M+48.9% | ||
| -$48.74M+16.8% | -$51.12M+16.2% | -$61.32M-40.7% | -$63.78M-74.3% | -$58.57M-45.5% | ||
| -2,500.7%-977pp | -1,260.8%+1,984pp | -1,392.9%+4,756pp | -1,498.3%+2,079pp | -1,524.1%+1,389pp | ||
| $897K+144% | $902K+139% | $538K+19.8% | $366K-18.8% | $368K+18.7% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$47.84M+17.8% | -$50.22M+17.2% | -$60.78M-40.9% | -$63.42M-75.5% | -$58.21M-45.7% | ||
| -2,454.6%-940pp | -1,238.5%+1,987pp | -1,380.7%+4,704pp | -1,489.7%+2,043pp | -1,514.6%+1,376pp | ||
| -$1.50+61.5% | -$1.64+65.6% | -$3.20+29.5% | -$3.84+12.1% | -$3.90+23.2% | ||
| -$46.4M+18.5% | -$48.93M+17.8% | -$59.15M-39.6% | -$61.88M-75.5% | -$56.93M-46.7% | ||
| -2,380.8%-899pp | -1,206.8%+1,960pp | -1,343.7%+4,630pp | -1,453.6%+1,994pp | -1,481.3%+1,326pp | ||
| -$48.74M+16.8% | -$51.12M+16.2% | -$61.32M-40.7% | -$63.78M-74.3% | -$58.57M-45.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Insight Molecular Diagnostics Inc. Common Stock's revenue?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) generated $1.9M in revenue over the trailing twelve months, down 49.3% year over year.
- Is Insight Molecular Diagnostics Inc. Common Stock profitable?
- Insight Molecular Diagnostics Inc. Common Stock is not currently profitable: it reported a net loss of $47.8M over the trailing twelve months, a -2454.6% net margin.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Gross margin is 51.3% and operating margin is -2500.7%, with a -2454.6% net margin.
- What is Insight Molecular Diagnostics Inc. Common Stock's earnings per share?
- Insight Molecular Diagnostics Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.50.
- Where does Insight Molecular Diagnostics Inc. Common Stock's income statement data come from?
- Every line is extracted from Insight Molecular Diagnostics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
